Answers are grounded in this paper and cite their sources.
The combination of BRAF-targeted agents with immune checkpoint inhibitors represents a recent advance in the treatment of melanoma, even though each of these therapeutic approaches alone has specific limitations. Increasing evidence suggests indeed the existence of a synergistic interaction between these therapeutic modalities.
No takes yet. Share an insight, caveat, or question.
Cooper et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: